Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2425 participants.
Also called NCT02586155
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 2,425 participants
- Registry
-
NCT02586155
-
- Main results
- Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
- Other papers using this trial's data
- Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Australia, Belgium, Bulgaria, Croatia, Germany, Hungary, Israel, Mexico, Netherlands, Poland, Russia, Serbia, Slovakia, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02586155. Randomized; triple masking; primary purpose prevention. Start 2015-11 (actual); primary completion 2020-11-30 (actual). Results posted on 2021-08-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
- Acronym
- BETonMACE
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Apabetalone
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Rosuvastatin
- Lead sponsor
- Resverlogix Corp
- Collaborator
- PPD Development, LP
- Collaborator
- ICON plc
- Collaborator
- Medidata Solutions
Record details
- Record id
cardio:ct-nct02586155- Content hash
a4db6173f9f1feabc441b359fdfdffd8449ded5d4b75f67454502e8adf0779a6